Foresee Pharmaceuticals Advances CAMCEVI with New 21 mg Prostate Cancer Injection Approval

Foresee Pharmaceuticals Advances Prostate Cancer Treatment with CAMCEVI 21 mg Approval

Foresee Pharmaceuticals Co. Ltd. is making significant strides in oncology with the recent announcement regarding their product, CAMCEVI. On March 6, 2026, the company confirmed that its partner, Accord Healthcare, received a favorable opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP). This recommendation pertains to an extension of the marketing authorization for CAMCEVI, specifically introducing a new 21 mg, 3-month ready-to-use injectable formulation, which targets advanced prostate cancer patients. The innovation in this formulation is noteworthy as it streamlines the treatment process by eliminating the intricate multi-step mixing procedures characteristic of traditional therapies, thereby improving patient and healthcare provider experiences.

The new 21 mg CAMCEVI formulation offers distinct advantages over the previously available 42 mg version, which had a 6-month dosing schedule. By presenting a more frequent, quarterly administration option, the 3-month formulation aims to enhance patient comfort and adherence to the treatment regimen. This development is particularly crucial, as consistent medication adherence is essential in managing advanced prostate cancer effectively. As the European Commission (EC) prepares to assess the CHMP's recommendation, a final decision on the marketing authorization is anticipated in the second quarter of 2026. If approved, Accord Healthcare will hold the exclusive rights to commercialize CAMCEVI across European markets, positioning the product as a vital option within the treatment landscape for this challenging disease.

Foresee Pharmaceuticals is building a robust portfolio with CAMCEVI leading the charge in advanced prostate cancer therapies. The 42 mg formulation already enjoys regulatory approval across multiple regions, including the U.S. and Canada, with a U.S. launch having occurred in April 2022. Furthermore, recent developments indicate the ongoing success of this product line, as the U.S. FDA approved CAMCEVI ETM in August 2025. Future expansion is on the horizon with ongoing regulatory reviews for the 3-month CAMCEVI version in the EU and the promising results from the CASPPIAN Phase 3 clinical trial, which will pave the way for a new drug application submission by mid-2026 for its application in treating central precocious puberty.

In addition to enhancing treatment options for prostate cancer, Foresee’s innovative approach underscores its commitment to improving patient outcomes through unambiguous formulations and convenient dosing intervals. With the healthcare landscape increasingly leaning toward patient-centric solutions, Foresee Pharmaceuticals exemplifies the transformative potential within oncology, ensuring patients have access to more manageable and effective treatments as the company continues to expand its reach in the pharmaceutical industry.